In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs)

Toxicology and Applied Pharmacology

Volumn 250, Issue 2, 2011, Pages 108-116

  Corsini, Emanuela ^a   Avogadro, Anna ^a   Galbiati, Valentina ^a   dell'Agli, Mario ^a   Marinovich, Marina ^a   Galli, Corrado L ^a   Germolec, Dori R ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cytokine; Immunosuppression; MMP 9; Perfluorinated compounds; PPAR receptor; Whole blood assay

Indexed keywords

GAMMA INTERFERON; GELATINASE B; I KAPPA B; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; PERFLUORO COMPOUND; PERFLUOROOCTANE; PERFLUOROOCTANESULFONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHYTOHEMAGGLUTININ; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME RELEASE; EVALUATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOTOXICITY; IN VITRO STUDY; LEUKOCYTE; PROTEIN DEGRADATION;

ALKANESULFONIC ACIDS; CELL LINE, TUMOR; CYTOKINES; FLUOROCARBONS; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKINS; LEUKOCYTES; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; OCTANOIC ACIDS; PPAR ALPHA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650561380     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.11.004     Document Type: Article

References (42)

1. Biegel L.B., Hurtt M.E., Frame S.R., O'Connor J.C., Cook J.C. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci. 2001, 60:44-55.
2. Bouhlel M.A., Staels B., Chinetti-Gbaguidi G. Peroxisome proliferator-activated receptors-from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J. Intern. Med. 2008, 263:28-42.
3. Brostjan C., Anrather J., Csizmadia V., Natarajan G., Winkler H. Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun. J. Immunol. 1997, 158:3836-3844.
4. Butenhoff J.L., Gaylor D.W., Moore J.A., Olsen G.W., Rodricks J., Mandel J.H., Zobel L.R. Characterization of risk for general population exposure to perfluorooctanoate. Regul. Toxicol. Pharmacol. 2004, 39:363-380.
5. Calafat A.M., Ye X., Silva M.J., Kuklenyik Z., Needham L.L. Human exposure assessment to environmental chemicals using biomonitoring. Int. J. Androl. 2006, 29:166-171.
6. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 2000, 49:497-505.
7. Crabtree G.R., Clipstone N.A. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu. Rev. Biochem. 1994, 63:1045-1083.
8. Cunard R. The potential use of PPARalpha agonists as immunosuppressive agents. Curr. Opin. Invest. Drugs 2005, 6:467-472.
9. Delayre-Orthez C., Becker J., Guenon I., Lagente V., Auwerx J., Frossard N., Pons F. PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir. Res. 2005, 6:91.
10. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation and control. Nature 1996, 384:39-43.
11. DeWitt J.C., Copeland C.B., Strynar M.J., Luebke R.W. Perfluorooctanoic acid-induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ. Health Perspect. 2008, 116:644-650.
12. DeWitt J.C., Copeland C.B., Luebke R.W. Suppression of humoral immunity by perfluorooctanoic acid is independent of elevated serum corticosterone concentration in mice. Toxicol. Sci. 2009, 109:106-112.
13. Emmett E.A., Zhang H., Shofer F.S., Freeman D., Rodway N.V., Desai C., Shaw L.M. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J. Occup. Environ. Med. 2006, 48:771-779.
14. Fromme H., Tittlemier S.A., Völkel W., Wilhelm M., Twardella D. Perfluorinated compounds-exposure assessment for the general population in Western countries. Int. J. Hyg. Environ. Health 2009, 212:239-270.
15. Guruge K.S., Hikono H., Shimada N., Murakami K., Hasegawa J., Yeung L.W., Yamanaka N., Yamashita N. Effect of perfluorooctane sulfonate (PFOS) on influenza A virus-induced mortality in female B6C3F1 mice. J. Toxicol. Sci. 2009, 34:687-691.
16. Kennedy G.L., Butenhoff J.L., Olsen G.W., O'Connor J.C., Seacat A.M., Perkins R.G., Biegel L.B., Murphy S.R., Farrar D.G. The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 2004, 34:351-384.
17. Lau C., Butenhoff J.L., Rogers J.M. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol. Appl. Pharmacol. 2004, 198:231-241.
18. Liu R.C., Hahn C., Hurtt M.E. The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Fundam. Appl. Toxicol. 1996, 30:102-108.
19. Liu R.C., Hurtt M.E., Cook J.C., Biegel L.B. Effect of the peroxisome proliferator, ammonium perfluorooctanoate (C8), on hepatic aromatase activity in adult male Crl:CDBR (CD) rats. Fundam. Appl. Toxicol. 1996, 30:220-228.
20. Olsen G.W., Burris J.M., Mandel J.H., Zobel L.R. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J. Occup. Environ. Med. 1999, 41:799-806.
21. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 2007, 115:1298-1305.
22. Pastoor T.P., Lee K.P., Perri M.A., Gillies P.J. Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. Exp. Mol. Pathol. 1987, 47:98-109.
23. Peden-Adams M.M., EuDaly J.G., Dabra S., EuDaly A., Heesemann L., Smythe J., Keil D.E. Suppression of humoral immunity following exposure to the perfluorinated insecticide sulfluramid. J. Toxicol. Environ. Health A 2007, 70:1130-1141.
24. Peden-Adams M.M., Keller J.M., Eudaly J.G., Berger J., Gilkeson G.S., Keil D.E. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 2008, 104:144-154.
25. Qazi M.R., Xia Z., Bogdanska J., Chang S.C., Ehresman D.J., Butenhoff J.L., Nelson B.D., DePierre J.W., Abedi-Valugerdi M. The atrophy and changes in the cellular compositions of the thymus and spleen observed in mice subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-alpha (PPARalpha). Toxicology 2009, 260:68-76.
26. Rayne S., Forest K. Perfluoroalkyl sulfonic and carboxylic acids: a critical review of physicochemical properties, levels and patterns in waters and wastewaters, and treatment methods. J. Environ. Sci. Health A Toxic/Hazard. Subst. Environ. Eng. 2009, 44:1145-1199.
27. Saccani S., Pantano S., Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol. 2002, 3:69-75.
28. Sambrook J., Russell D.W. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 3rd ed.
29. Schmitz M.L., Bacher S., Kracht M. I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem. Sci. 2001, 26:186-190.
30. Schreiber E.P., Matthias M.M., Schaffner W. Rapid detection of octameric binding proteins with mini-extract prepared from a small number of cells. Nucleic Acids Res. 1989, 17:6419-6422.
31. Shu H., Wong B., Zhou G., Li Y., Berger J., Woods J.W., Wright S.D., Cai T.Q. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 2000, 267:345-349.
32. Steenland K., Fletcher T., Savitz D.A. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ. Health Perspect. 2010, 118:1100-1108.
33. Suja F., Pramanik B.K., Zain S.M. Contamination, bioaccumulation and toxic effects of perfluorinated chemicals (PFCs) in the water environment: a review paper. Water Sci. Technol. 2009, 60:1533-1544.
34. Takacs M.L., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol. Sci. 2007, 95:108-117.
35. Tsimihodimos V., Liberopoulos E., Elisaf M. Pleiotropic effects of fenofibrate. Curr. Pharm. Des. 2009, 15:517-528.
36. Vanden Berghe W., Vermeulen L., Delerive P., De Bosscher K., Staels B., Haegeman G. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv. Exp. Med. Biol. 2003, 544:181-196.
37. Vermeulen L., De Wilde G., Notebaert S., Vanden Berghe W., Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem. Pharmacol. 2002, 64:963-970.
38. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003, 22:1313-1324.
39. Viatour P., Merville M.P., Bours V., Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 2005, 30:43-52.
40. Yang Q., Xie Y., Eriksson A.M., Nelson B.D., DePierre J.W. Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem. Pharmacol. 2001, 62:1133-1140.
41. Yang Q., Xie Y., Alexson S.E., Nelson B.D., DePierre J.W. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 2002, 63:1893-1900.
42. Yang Q., Abedi-Valugerdi M., Xie Y., Zhao X.Y., Möller G., Nelson B.D., DePierre J.W. Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2002, 2:389-397.